Reference number(s)
3070-H

SPECIALTY QUANTITY LIMIT PROGRAM

VALCYTE (valganciclovir)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Valcyte (valganciclovir) 450 mg tablet	102 tablets per 30 days	Treatment of CMV Retinitis in Adults: Induction: 900 mg orally twice a day for 21 days Maintenance: 900 mg orally once a day Prevention of CMV Disease in Adults: 900 mg once a day Prevention of CMV Disease in Pediatric Patients: Dosage calculated based on BSA and CrCl given once a day, with maximum dose 900 mg
Valcyte (valganciclovir hydrochloride) for oral solution 50 mg/mL	1000 mL per 30 days	

Abbreviations: CMV = cytomegalovirus; BSA = body surface area; CrCl = creatinine clearance

III. REFERENCES

1. Valcyte [package insert]. South San Francisco, CA: Genentech USA, Inc.; August 2018.

CVS caremark™